AR126351A1 - Compuestos y sus sales inhibidores del inflamasoma nlrp3 - Google Patents
Compuestos y sus sales inhibidores del inflamasoma nlrp3Info
- Publication number
- AR126351A1 AR126351A1 ARP220101723A ARP220101723A AR126351A1 AR 126351 A1 AR126351 A1 AR 126351A1 AR P220101723 A ARP220101723 A AR P220101723A AR P220101723 A ARP220101723 A AR P220101723A AR 126351 A1 AR126351 A1 AR 126351A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- independently selected
- nlrp3
- salts
- inflamasoma
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 150000003839 salts Chemical class 0.000 title abstract 3
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 108091008099 NLRP3 inflammasome Proteins 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La memoria descriptiva se refiere en general a compuestos de fórmula (1) y sales farmacéuticamente aceptables de los mismos. Dichos compuestos son útiles para inhibir la actividad del inflamasoma NLRP3 y pueden ser útiles como agentes terapéuticos. La memoria descriptiva también se refiere al uso de dichos compuestos para tratar o prevenir enfermedades y afecciones en las que está implicado el inflamasoma NLRP3. La memoria descriptiva se refiere además a composiciones que comprenden dichos compuestos. Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1) o una sal farmacéuticamente aceptable del mismo, en donde R¹ se selecciona entre los compuestos del grupo de fórmulas (2); cada R³ se selecciona independientemente entre -H y -alquilo C₁₋₃; R⁴ se selecciona entre -H y -alquilo C₁₋₃; R²A, R²B, R²C y R²D se seleccionan cada uno independientemente entre -H, -F, -Cl, -alquilo C₁₋₃ sustituido con 0 - 3 sustituyentes -F, ciclopropilo, -OCF₃ y -SO₂Me; W, X, Y y Z se seleccionan cada uno independientemente entre CR⁵ y N; cero o uno de W, X, Y y Z son N y el resto de W, X, Y y Z son CR⁵; cada R⁵ se selecciona independientemente entre -H, -Me y -F.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217970P | 2021-07-02 | 2021-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126351A1 true AR126351A1 (es) | 2023-10-11 |
Family
ID=82611090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101723A AR126351A1 (es) | 2021-07-02 | 2022-07-01 | Compuestos y sus sales inhibidores del inflamasoma nlrp3 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11970463B2 (es) |
| EP (1) | EP4363406A1 (es) |
| JP (1) | JP2024523623A (es) |
| KR (1) | KR20240031343A (es) |
| CN (1) | CN117580826A (es) |
| AR (1) | AR126351A1 (es) |
| AU (1) | AU2022304254A1 (es) |
| BR (1) | BR112023026976A2 (es) |
| CA (1) | CA3224513A1 (es) |
| CL (1) | CL2023003939A1 (es) |
| CO (1) | CO2024000565A2 (es) |
| CR (1) | CR20240038A (es) |
| DO (1) | DOP2024000002A (es) |
| EC (1) | ECSP24008862A (es) |
| IL (1) | IL309680A (es) |
| MX (1) | MX2024000234A (es) |
| TW (1) | TW202321201A (es) |
| UY (1) | UY39839A (es) |
| WO (1) | WO2023275366A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CN115417856A (zh) * | 2021-09-30 | 2022-12-02 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| WO2024141534A1 (en) * | 2022-12-28 | 2024-07-04 | Astrazeneca Ab | Crystalline forms of nlrp3 inflammasome inhibitors, chemical processes and chemical compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1984904A (zh) | 2004-05-08 | 2007-06-20 | 神经能质公司 | 3－芳基－5,6－二取代哒嗪 |
| EP3707134A1 (en) | 2017-11-09 | 2020-09-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| WO2021193897A1 (ja) | 2020-03-27 | 2021-09-30 | アステラス製薬株式会社 | 置換ピリダジン化合物 |
| CN116390914A (zh) * | 2020-12-25 | 2023-07-04 | 上海拓界生物医药科技有限公司 | 一类含哒嗪的化合物及其医药用途 |
| CN116867769A (zh) | 2021-02-08 | 2023-10-10 | 南京明德新药研发有限公司 | 取代的哒嗪苯酚类衍生物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CA3218212A1 (en) | 2021-04-28 | 2022-11-03 | Astellas Pharma Inc. | Substituted triazine compound |
| JP2024529839A (ja) | 2021-06-29 | 2024-08-14 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
-
2022
- 2022-07-01 AU AU2022304254A patent/AU2022304254A1/en active Pending
- 2022-07-01 JP JP2023580488A patent/JP2024523623A/ja active Pending
- 2022-07-01 WO PCT/EP2022/068292 patent/WO2023275366A1/en active Application Filing
- 2022-07-01 IL IL309680A patent/IL309680A/en unknown
- 2022-07-01 MX MX2024000234A patent/MX2024000234A/es unknown
- 2022-07-01 CN CN202280045960.2A patent/CN117580826A/zh active Pending
- 2022-07-01 KR KR1020247003701A patent/KR20240031343A/ko unknown
- 2022-07-01 EP EP22744149.0A patent/EP4363406A1/en active Pending
- 2022-07-01 BR BR112023026976A patent/BR112023026976A2/pt unknown
- 2022-07-01 CA CA3224513A patent/CA3224513A1/en active Pending
- 2022-07-01 US US17/810,367 patent/US11970463B2/en active Active
- 2022-07-01 CR CR20240038A patent/CR20240038A/es unknown
- 2022-07-01 AR ARP220101723A patent/AR126351A1/es unknown
- 2022-07-01 TW TW111124687A patent/TW202321201A/zh unknown
- 2022-07-04 UY UY0001039839A patent/UY39839A/es unknown
-
2023
- 2023-12-28 CL CL2023003939A patent/CL2023003939A1/es unknown
-
2024
- 2024-01-02 DO DO2024000002A patent/DOP2024000002A/es unknown
- 2024-01-24 CO CONC2024/0000565A patent/CO2024000565A2/es unknown
- 2024-02-02 EC ECSENADI20248862A patent/ECSP24008862A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3224513A1 (en) | 2023-01-05 |
| BR112023026976A2 (pt) | 2024-03-12 |
| US20230110122A1 (en) | 2023-04-13 |
| CL2023003939A1 (es) | 2024-08-30 |
| CR20240038A (es) | 2024-05-24 |
| IL309680A (en) | 2024-02-01 |
| AU2022304254A1 (en) | 2024-02-08 |
| DOP2024000002A (es) | 2024-05-15 |
| ECSP24008862A (es) | 2024-03-01 |
| US11970463B2 (en) | 2024-04-30 |
| WO2023275366A1 (en) | 2023-01-05 |
| UY39839A (es) | 2023-01-31 |
| TW202321201A (zh) | 2023-06-01 |
| CO2024000565A2 (es) | 2024-04-18 |
| MX2024000234A (es) | 2024-04-16 |
| KR20240031343A (ko) | 2024-03-07 |
| EP4363406A1 (en) | 2024-05-08 |
| JP2024523623A (ja) | 2024-06-28 |
| CN117580826A (zh) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126351A1 (es) | Compuestos y sus sales inhibidores del inflamasoma nlrp3 | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| PE20230825A1 (es) | Inhibidores de kras triciclicos fusionados | |
| PE20221905A1 (es) | Aminas biciclicas como inhibidoras de la cdk2 | |
| CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
| ECSP22011086A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| AR090589A1 (es) | INHIBIDORES DE b-LACTAMASA ISOXAZOL | |
| AR078157A1 (es) | Derivados de pirazol-[4,5-d]pirrolo[2,3-b]piridina inhibidores de tirosinquinasas jak 2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer | |
| AR057109A1 (es) | Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento | |
| AR098776A1 (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas | |
| AR076714A1 (es) | Agonistas del receptor de glucocorticoides | |
| AR109437A1 (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| AR121269A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa / fosfodiesterasa 1 (enpp1) y métodos de uso de los mismos | |
| CO2022015157A2 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| AR109387A1 (es) | INHIBIDORES DEL FACTOR XIa | |
| AR123435A1 (es) | Derivados de sulfamoil urea que contienen resto alquilo-oxacicloalquilo, y usos de los mismos | |
| AR108535A1 (es) | Derivados de tetrahidropirano y tiopirano que tienen actividad multimodal contra el dolor | |
| AR127235A1 (es) | Pirazoloquinolinas inhibidoras de kras | |
| AR088002A1 (es) | Derivados de metansulfonamida sustituidos con arilo o n-heteroarilo como ligandos del receptor vanilloide |